drugset / Trial / NCT00125008

Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever

NCT00125008 ↗

RandomizedParallel-groupQuadruple-blindPrevention

Summary

This study is part of the International Vaccine Institute's (IVI's) typhoid Vi demonstration project that aims to accelerate the rational introduction of Vi vaccines in typhoid endemic countries. The purpose of this study is to determine the effectiveness of the Vi vaccine following a mass typhoid immunization campaign in an endemic area in Kolkata, India. The cost-effectiveness of the Vi vaccination and the logistic feasibility of a mass typhoid immunization campaign will also be evaluated.

Timeline

Start
2003-05
Primary completion
2008-01
Completion
2008-01

Outcome

Met primary endpoint

paper Typhoid fever was diagnosed in 96 subjects in the hepatitis A vaccine group, as compared with 34 in the Vi vaccine group PMID 19625715 ↗

paper The level of protective effectiveness for the Vi vaccine was 61% (95% confidence interval [CI], 41 to 75; P<0.001 PMID 19625715 ↗

Drugs

EvaluationDrugModalityDoseRoute
Comparator Hepatitis A vaccine Vaccine 720 unknown —
Comparator Hepatitis A vaccine Vaccine 1440 unknown —
Subject Typhoid Vi vaccine Vaccine 25 ug —
Subject Typhoid Vi vaccine Vaccine 0.5 ml —